Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility
NASDAQ | TSX: ACB
Company's Long-Standing Investment in Operational Excellence Continues with Industry Leading Upgrades and Renaming the Facility to Aurora Alpine
EDMONTON, AB, April 30, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora's proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions, expanded output, and superior product quality. The site has been renamed to Aurora Alpine – a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley.
"Over the last three years, the investments we've made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%," says Alex Miller, Executive Vice President of Operations and Supply Chain at Aurora. "The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that's driven by industry leading genetic technology, and backed by a world-class team that make it all possible."
The former Whistler Medical Marijuana Company site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally.
Aurora continues to advance the frontiers of operational excellence through the integration of cutting-edge cultivation technologies and proprietary genetics. These advancements have not only increased manufacturing capabilities, but have also set new industry standards for operational efficiency and cultivation precision. These continuous improvements are what solidifies Aurora as a global leader that continues to shape the future of the cannabis industry.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Contact
For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com
For Investors: ICR, Inc. | aurora@icrinc.com
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's improvements at its facility located in Pemberton, BC and the anticipated benefits, including expanded capacity, superior growing practices, optimal cultivating conditions, and the ability for Aurora to expand its global reach by exporting premium medical cannabis produced from that facility internationally, as well as statements regarding the Company's commitment to continuous improvement and operational excellence.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-the-completion-of-a-multimillion-dollar-investment-and-renaming-of-bc-manufacturing-facility-302441872.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/30/c3502.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus', 'SLP'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one meetings with institutional investors on Tuesday, June 17, 2025. For more information about the events or questions about registration, interested parties should reach out to their contacts at Citizens. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Yahoo
13 minutes ago
- Yahoo
CoreWeave (CRWV) Slumps as DA Davidson Estimates Equity Worth Under $5
CoreWeave (CRWV, Financials) dropped 6% Tuesday after DA Davidson analyst Gil Luria reaffirmed an Underperform rating and raised red flags over the company's leveraged financing model and residual asset risks. Warning! GuruFocus has detected 10 Warning Signs with CRWV. The AI hyperscaler, which rents GPU-based compute infrastructure and maintains strong ties to Nvidia (NVDA, Financials), has surged over 300% since its IPO debut in March. But Luria said the company's pro forma financing structure offers little return for current equity holders, noting that "there is no upfront equity, and no returns to current equity holders during the contract." CoreWeave's proposed infrastructure model assumes a 15% equity input and 85% loan-to-value financing, but Luria highlighted reliance on high-cost debtvendor financing, unsecured notes, and credit lines with rates as high as 9.5%. DA Davidson estimates the company may face $590 million in extra debt servicing costs. Luria also flagged GPU depreciation risks, citing Amazon Web Services' recent 50% price cut on H200 chips. He projected that resale values could fall below 25% of original prices within four years, undermining assumptions of residual asset worth. The company's own materials assumed 9% loan rates, but filings show a blended 12.5% cost. The entire value of the enterprise is owned by the debt holders, Luria wrote, discounting future asset values and projecting equity could be worth under $5 per share within four yearstranslating to an enterprise value of less than $7.5 billion. Luria said the only way to justify near-term optimism is if CoreWeave can raise more than $10 billion in equity at current valuations. That could support two years of buildout, he wrote, though it would significantly dilute current shareholders. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Exclusive-French cognac makers offer China minimum import prices to fend off tariffs
By Tassilo Hummel and Emma Rumney PARIS/LONDON (Reuters) -Negotiators representing French cognac producers suggested minimum prices for exports to China of between $20 and around $300 per litre as an opening bid in talks aimed at ending a tariff stand-off with China, a document seen by Reuters shows. The minimum prices are part of efforts to avoid permanent tariffs of up to 39% amid tense negotiations with China's commerce ministry, which has opened an anti-dumping investigation focused on the sector. They were sent to producers several weeks ago for their approval by a Paris-based law firm negotiating on the spirit makers' behalf. A spokesperson for the law firm, GIDE, declined to comment. The industry, grappling with falling sales and simultaneous tariff threats from the United States, its other key market, has been fighting to secure a deal with China since Beijing first threatened to levy the duties in January 2024. The move came amid a wider trade dispute with the European Union after it imposed tariffs on imports of Chinese electric vehicles. A flurry of political meetings in Paris and technical discussions in Beijing last week raised hopes that a settlement of the trade spat was imminent. But the talks ended with no deal, leaving just weeks to go before a July 5 deadline for Beijing to wrap up its anti-dumping probe. Chinese authorities subsequently announced that the industry had made a voluntary "price pledge" and it was reviewing its terms. The price list seen by Reuters included a "minimum import price" for different bands of cognac defined by how long the spirit has been aged, ranging from two years for the cheapest "Very Special" (VS) cognacs to the most expensive "Extra Extra Old" (XXO), aged 14 years or more. Under the offer, VS cognac would have a minimum import price of 144.70 yuan ($20.16) per litre, while "Very Superior Old Pale" (VSOP), aged for at least four years, would be priced at 177.92 yuan. High-end "Extra Old" (XO) would cost 526.52 yuan to import, with the XXO category, where prices reach thousands of dollars per bottle and more, costing at least 2,126.07 yuan ($296.16) per litre. France's BNIC industry body declined to comment on the prices, citing confidential negotiations. "We keep waiting and hoping for a good outcome," a BNIC spokesperson said. The prices in the document refer to the price paid for cognac by importers in China, with distributors, wholesalers, retailers and consumers paying more to buy it. Reuters was not able to determine current import prices across the sector, led by LVMH's Hennessy, Pernod Ricard's Martell and Remy Cointreau's Remy Martin. Hennessy's VS cognac currently sells to consumers for around $100 per litre on Tmall. Remy Martin's cheapest label meanwhile fetches around $110 to $350 for its XO cognac. TALKS ONGOING Chinese authorities have already imposed steep provisional duties on imports of European brandy - mostly made up of French cognac - in the dispute with the EU. Laurence Whyatt, analyst at Barclays, said it wasn't clear the industry had made a major concession in the price offer seen by Reuters. "Import prices are usually a third to a half of the retail price, so the prices detailed appear commensurate to the existing import prices," he said. However, the document seen by Reuters reflected the sector's opening offer and talks are ongoing. A source familiar with the discussions said after weeks of back and forth, the two sides seem potentially close to agreement, but another person said the talks were tough and the sector was being pushed to make a bad deal. A settlement with China, the most important export country by value for France's $3 billion cognac industry, that removes the duties would be a boon for the sector, whose growth prospects have been hurt by the tariff dispute. ($1 = 7.1788 Chinese yuan renminbi) Sign in to access your portfolio
